Remote electrical neuromodulation (REN) is USFDA cleared device for acute and/or preventive treatment of migraine in patients aged 12 + years of age. Each device has 18 sessions and for each session, the patients are recommended to use the intensity levels, which is “strong but not painful’. Here we report the data of the intensity levels used by the migraine patients in India. 

From the cloud database, we extratcted the device utilization data of Nerivio users in India who used the device between October 2023 to May 2025. With the help of telephonic survey, patient feedback was captured to assess the level of relief reported after using Nerivio.  Sessions with an average duration of >20 minutes and minimum intensity levels were analyzed for assessing average intensity levels  and its co relationship with age, gender, number of devices and response rates.

Total of 53, 2254 sessions taken by 2500+ patients were analyzed. Average intensity used by the patients was 38.19%. Males utilized higher intensity levels compared to females (42% vs 37%). Likewise, patients in the higher age group tolerated greater intensity levels (40% among patients age 41-50 years versus 37% among patients 21-30 years of age). ~37% patients used more than 1 device and such patients used greater intensity levels compared to those who used 1 device only. With single device, ~6 out of 10 patients report relief; responder rate is better with adhering.

Patients in India tolerated an average intensity level of 38%. Male gender, increased age and usage of ≥1 device was associated with patients utilizing greater average intensity levels.